Treatment to combat mustard gas

The US Biomedical Advanced Research and Development Authority (BARDA) has invested $43 million in Israel’s MediWound to develop its NexoBrid product for the treatment of mustard gas injuries. In 2015 BARDA invested $112 million to help MediWound develop NexoBrid for burns.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *